A5088488154- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Estrogen and related hormone effects
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- PI3K/AKT/mTOR signaling in cancer
- Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Breast Lesions and Carcinomas
- Neuroendocrine Tumor Research Advances
- BRCA gene mutations in cancer
- Peptidase Inhibition and Analysis
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Economic and Financial Impacts of Cancer
- COVID-19 and healthcare impacts
- Bone health and treatments
- MicroRNA in disease regulation
- Chemotherapy-induced cardiotoxicity and mitigation
University of Modena and Reggio Emilia
2016-2025
Azienda Ospedaliero-Universitaria di Modena
2015-2025
Italian Oncology Group of Clinical Research
2019-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2013-2019
Ospedale Santa Chiara
2019
Istituto Oncologico Veneto
2013-2018
Guglielmo da Saliceto Hospital
2018
Azienda Ospedaliero-Universitaria Careggi
2017
Istituti Ospitalieri di Cremona
2009-2016
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2011-2016
This is a noncomparative, randomized, phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib patients human epidermal growth factor receptor 2 (HER2) -positive, stage to IIIA operable breast cancer. The primary aim was estimate the percentage pathologic complete response (pCR; no invasive tumor and axillary nodes).In three arms, chemotherapy consisted weekly paclitaxel (80 mg/m(2)) for 12 weeks followed by...
Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy less extended exposure under investigation. short-HER study was aimed to assess non-inferiority 9 weeks versus 1 year combined with chemotherapy.HER2-positive cancer patients node-positive or, if node negative, at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age ≤35 years, or hormone receptor negativity) were randomly assigned receive sequential...
Abstract Introduction. The assessment of hormone receptors (HRs) and human epidermal growth factor receptor (HER)-2 is necessary to select patients who are candidates for hormonal anti–HER-2 therapy. evaluation these parameters generally carried out in primary tumors it not clear if reassessment metastatic lesions might have an impact on patient management. aim this analysis was compare HER-2 HR status versus sites breast cancer patients. Patients Methods. Seventy-five with available samples...
BackgroundThere is the need to identify new prognostic markers refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was evaluate association tumor-infiltrating lymphocytes (TILs) with distant disease-free survival (DDFS) in patients enrolled ShortHER adjuvant trial which compared 9 weeks versus 1-year trastuzumab addition chemotherapy, and test interaction between TILs treatment arm.Patients methodsStromal were assessed 866 cases on centralized...
LBA500 Background: Prognosis of pts with early triple negative breast cancer (TNBC) is still poor and new effective treatments are needed. TNBC the most immunogenic BC subtype, this may account for sensitivity to immune checkpoint inhibitors. The A-BRAVE trial was designed evaluate efficacy avelumab, an anti PD-L1 antibody, as adjuvant treatment at high risk. Methods: This a phase III, multicentric, randomized study comparing 1 year avelumab vs observation considered risk relapse. Pts were...
Importance For patients with early ERBB2 (formerly HER2 )–positive breast cancer, there is a need to identify biomarkers guide treatment de-escalation. Objective To evaluate the association of tumor-infiltrating lymphocytes (TILs) distant disease-free (DDFS) and overall survival (OS) for -positive cancer. Design, Setting, Participants The ShortHER randomized clinical trial was multicentric in Italy that enrolled cancer from December 2007 October 2013. Patients received 9 weeks or 1 year...
Tumor-infiltrating lymphocytes (TILs) evaluated in primary breast cancer (BC) convey prognostic information. Limited data the metastatic setting are available. Secondary lesions from 94 BC patients, 43 triple-negative (TN) and 51 HER2-positive, were for TILs expression of CD8, FOXP3, PD-L1 by immunohistochemistry. levels on metastasis generally low (median 5%) did not differ between TN HER2+ tumors. Younger patients showed significantly lower (p = 0.002). In higher lung metastases as...
Proton-pump-inhibitors (PPIs) are frequently prescribed for the management of anticancer drug-related gastrointestinal symptoms. Palbociclib is a weak base with pH-dependent solubility and potential drug-drug interaction at absorption level may affect clinical pharmacokinetics. The current study was aimed investigating effect co-administration PPIs palbociclib on progression-free survival (PFS) in metastatic breast cancer (mBC) patients.Patients affected by estrogen receptor-positive, human...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned coprimary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.We present final analysis of phase III noninferiority, randomized ShortHER comparing 9 weeks versus 1 year adjuvant...
// Patrizia Vici 1 , Laura Pizzuti Andrea Michelotti 2 Isabella Sperduti 3 Clara Natoli 4 Lucia Mentuccia 5 Luigi Di Lauro Domenico Sergi Paolo Marchetti 6 Daniele Santini 7 Emanuela Magnolfi Iezzi Luca Moscetti 8 Agnese Fabbri 9 Alessandra Cassano 10 Antonino Grassadonia Claudia Omarini 11 Federico Piacentini Botticelli Ilaria Bertolini Angelo Fedele Scinto 12 Germano Zampa 13 Maria Mauri 14 Loretta D'Onofrio Valentina Sini Maddalena Barba Marcello Maugeri-Saccà Ernesto Rossi Elisabetta...
Purpose This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor (HR) –positive/human epidermal growth factor 2 (HER2) –negative operable breast cancer. Methods Ninety-two postmenopausal women with stage II IIIA primary cancer were randomly assigned preoperative consisting 6 months 2.5 mg orally daily 1,500 placebo. Surgery was performed within weeks from...